Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal S230815 in paediatric KCNT1-related developmental and epileptic encephalopathy
2024-513332-17-00Phase 2Authorised
- Sponsor
- Servier
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of nivolumab + ipilimumab in epileptic encephalopathy, Malignant Migrating Partial Seizures of Infancy (MMPSI) and early infantile epileptic encephalopathy (EIEE), sponsored by Servier. Primary endpoint: Incidence and severity of adverse events. Planned start Aug 2025; status: authorised.
02
Drugs
nivolumab + ipilimumab
03
Conditions
epileptic encephalopathyMalignant Migrating Partial Seizures of Infancy (MMPSI)early infantile epileptic encephalopathy (EIEE)
Beyond the preview
Go deeper on 2024-513332-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513332-17-00.